Specialized Clinical Trial Site Management Organization BN000073850
The Company is a leading clinical trial site management organization (SMO) specializing in in vitro diagnostic (IVD) study sites for point-of-care (POC) and over-the-counter (OTC) rapid diagnostic tests. The Company partners with a diverse network of community based outpatient clinics across multiple states, embedding experienced clinical research coordinators (CRCs) directly into partner sites to drive decentralized trial enrollment without disrupting clinic operations.
Key Aspects
· The Company generated a 20.2% revenue CAGR from 2022 to 2025, while adjusted EBITDA increased at a 22.9% CAGR over the same period.
· The Company operates a decentralized SMO model, partnering with independent clinics across multiple states.
· The Company focuses on FDA-approval IVD studies for POC and OTC rapid diagnostics.
· The Company embeds employed CRCs within partner clinics to ensure seamless execution.
Opportunities
· Expand existing sponsor relationships through increased repeat study volume and broader service offerings.
· Broaden the clinical site network across additional specialties to support higher-complexity trials.
· Launch full-service clinical research capabilities to provide end-to-end solutions beyond site management.
· Pursue higher-value study categories that command significantly higher per-subject economics.
Headquartered
· Alabama, United States
Current Markets
· The Company serves both sponsors & clinical research organizations (CROs), as well as trial site partners. The Company offers their services across multiple U.S. states.
Shareholder Objectives
· The Owner is seeking a transaction with an investor with scaling experience who can help support the Company's next phase of growth.
